Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects

British Journal of Clinical Pharmacology

Volumn 74, Issue 6, 2012, Pages 978-989

  Nicolas, Laurent B ^a   Krause, Andreas ^a   Gutierrez, Marcelo M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Epoprostenol; Haemodynamics; Pharmacokinetics; Prostacyclin

Indexed keywords

6 KETO PROSTACYCLIN F1ALPHA; 6,15 DIKETO 13,14 DIHYDRO PROSTACYCLIN F1ALPHA; PROSTACYCLIN; TEZOSENTAN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOOD INTAKE; HEADACHE; HEART INDEX; HEART OUTPUT; HEART RATE; HUMAN; HUMAN EXPERIMENT; JAW PAIN; MALE; MEAN ARTERIAL PRESSURE; MUSCLE TIGHTNESS; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; HEART RATE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84869040387     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04301.x     Document Type: Article

References (36)

1. Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007; 58: (Suppl. 5): 591-602.
2. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44: 14-30.
3. Chaumais MC, Jobard M, Huertas A, Vignand-Courtin C, Humbert M, Sitbon O, Rieutord A, Montani D. Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opin Drug Metab Toxicol 2010; 6: 1587-98.
4. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-65.
5. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta 2009; 403: 9-16.
6. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
7. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-5.
8. Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007; 3: 887-900.
9. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
10. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
11. Raja SG, Dreyfus GD. Current status of bosentan for treatment of pulmonary hypertension. Ann Card Anaesth 2008; 11: 6-14.
12. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
13. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali SM, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn Jr SD, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
14. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23: 595-600.
15. Roeleveld RJ, Vonk-Noordegraaf A, Marcus JT, Bronzwaer JG, Marques KM, Postmus PE, Boonstra A. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 2004; 125: 572-9.
16. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-65.
17. GlaxoSmithKline. Flolan® prescribing information dated March 2011. Available at http://us.gsk.com/products/assets/us_flolan.pdf (last accessed 21 May 2012).
18. Gough K. Assessment of dose proportionality: reports from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working group. Drug Inf J 1995; 29: 1039-48.
19. Olanoff LS, Walle T, Cowart TD, Walle UK, Oexmann MJ, Conradi EC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther 1986; 40: 408-14.
20. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides. Ellicott City, MD: Icon Development Solutions, 2009.
21. Macey R, Oster G, Zahnley T. Berkeley Madonna user's guide version 8.0.2. Berkeley CA. 2009.
22. Ihaka R, Gentleman R. R: a language for data analysis and graphic. J Comput Graph Stat 1996; 5: 299-314.
23. Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR, Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976; 12: 915-28.
24. Barrow SE, Dollery CT, Heavey DJ, Hickling NE, Ritter JM, Vial J. Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol 1986; 87: 243-7.
25. Desai UA, Deo SK, Hyland KV, Poon M, Daunert S. Determination of prostacyclin in plasma through a bioluminescent immunoassay for 6-keto-prostaglandin F1alpha: implication of dosage in patients with primary pulmonary hypertension. Anal Chem 2002; 74: 3892-8.
26. Rosenkranz B, Fischer C, Frolich JC. Prostacyclin metabolites in human plasma. Clin Pharmacol Ther 1981; 29: 420-4.
27. Food and Drug Administration US. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products- general considerations. 2001.
28. Daneshmend TK, Roberts CJ. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol 1982; 14: 73-8.
29. Lundin P, Naber T, Nilsson M, Edsbacker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Aliment Pharmacol Ther 2001; 15: 45-51.
30. Burggraaf J, Schoemaker HC, Cohen AF. Assessment of changes in liver blood flow after food intake - comparison of ICG clearance and echo-Doppler. Br J Clin Pharmacol 1996; 42: 499-502.
31. Kisch-Wedel H, Kemming G, Meisner F, Flondor M, Kuebler WM, Bruhn S, Koehler C, Zwissler B. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo. Intensive Care Med 2003; 29: 1574-83.
32. Nielsen CB, Bech JN, Pedersen EB. Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study. Br J Clin Pharmacol 1997; 44: 471-6.
33. Szczeklik J, Szczeklik A, Nizankowski R. Haemodynamic changes induced by prostacyclin in man. Br Heart J 1980; 44: 254-8.
34. Warrington SJ, Smith PR, O'Grady J. Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man. Eur J Cardiol 1980; 12: 73-80.
35. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334-8.
36. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-7.